{"schema_version":"secwatch.filing_event.v1","accession":"0001099800-23-000019","form_type":"8-K","ticker":"EW","cik":"0001099800","company_name":"Edwards Lifesciences Corp","filed_at":"2023-04-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:37.939183+00:00","generated_at":"2026-06-16T11:42:15.513542+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Edwards Q1 sales $1.46B (+9% YoY), adj EPS $0.62; raises FY guidance, CEO to retire","bullets":["Q1 GAAP EPS $0.56; adjusted EPS $0.62 vs prior guidance implied range.","TAVR sales $948M (+8% YoY, +11% cc); TMTT $42M; Surgical $248M; Critical Care $222M.","Full-year sales guidance raised to high end of $5.6-6.0B; adj EPS guidance raised to $2.48-2.60.","Repurchased ~$250M stock in Q1; free cash flow $253M.","CEO Michael Mussallem retiring next month; Bernard Zovighian to succeed."],"urls":{"canonical":"https://secwatch.observer/filing/0001099800-23-000019","json":"https://secwatch.observer/filing/0001099800-23-000019.json","markdown":"https://secwatch.observer/filing/0001099800-23-000019.md","text":"https://secwatch.observer/filing/0001099800-23-000019.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1099800/000109980023000019/0001099800-23-000019-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1099800/000109980023000019/ew-20230426.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T11:42:15.513542+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"dd8257a3605989b94758ff01e3145a3ec0f7a69a","claim":"Edwards Lifesciences Corp reported the quarter ended March 31, 2023 results: revenue $1.46 billion, EPS $0.56. Guidance raised.","evidence_excerpt":"April 26, 2023 — Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended March 31, 2023. Highlights and Outlook • Q1 sales grew 9 percent to $1.46 billion; constant currency 1 sales grew 13 percent • Q1 TAVR sales grew 8 percent; constant currency sales grew 11 percent • Q1 EPS of $0.56; adjusted 1 EPS of $0.62 • Repurchased","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1099800/000109980023000019/0001099800-23-000019-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2023"},{"label":"Revenue","value":"$1.46 billion"},{"label":"EPS","value":"$0.56"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}